Durrer prizes 2011

Cardiolog

Does heart rate influence CMR image quality of the coronary vessel wall?

Cardiolog

European National Society Cardiovascular Journals - Background, rationale and mission statement of the “Editors´ Club"

Cardiovascular scientific production in Europe is growing both in quantity and in quality. Promoting high-quality research is a major goal of the European Society of Cardiology (ESC). The ESC has two highly respected official general journals, namely the European Heart Journal and Cardiovascular Research, devoted to clinical and basic research respectively. The ESC also publishes several sub-speciality official journals covering the full spectrum of cardiovascular diseases and related techniques. Most European countries, however, also have their own cardiovascular journals. National Society Cardiovascular Journals (NSCJ) are time-honoured and classically disseminate high-quality scientific research mainly originating from each particular European country. They also play a major role in education and harmonisation of clinical practice. Most NSCJ are published in local languages but many of them also incorporate English editions. Altogether, NSCJ provide a highly effective means to disseminate cardiovascular research produced in Europe. Scientific knowledge, however, has no barriers and many of these journals have gained an undisputed international profile. Some NSCJ, however, are just emerging and would benefit from networking support. It became clear that enhancing collaboration among NSCJ Editors would facilitate advancement in knowledge and further diffusion of scientific and educative contents.Developing a “Constitution Document” and “Mission Statement” was considered desirable to set the basis of future collaboration among NSCJ Editors. We assumed this responsibility in recognising the crucial role of NSCJ in Europe. Our target was to produce and issue a core document with fundamental principles upon which all NSCJ Editors would agree. Common goals will be identified and agreed-on measures will be pursued. The constitution document presented herein was therefore developed to formalise the NSCJ Editors´ Club Task Force

Reduction of radiation dose using 80 kV tube voltage: a feasible strategy?

Cardiolog

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.

The aim of this pharmacokinetic/pharmacodynamic study was to define the relationships of the carboplatin exposure with the toxicity in patients treated with high dose carboplatin (400 mg m-2 day-1), cyclophosphamide (1500 mg m-2 day-1) and thiotepa (120 mg m-2 day-1) for four consecutive days, followed by peripheral stem cell transplantation. Exposure to carboplatin was studied in 200 treatment days by measuring the area under the carboplatin plasma ultrafiltrate (pUF) concentration vs time curve (AUC). The AUC was obtained by using a previously validated limited sampling model. A total of 31 patients was studied who received one, two or three courses of this high-dose chemotherapy regimen. The unbound, plasma ultrafiltrate carboplatin was almost completely cleared from the body before each next treatment day in a course; the day-to-day AUC variation was 3.3%. The mean cumulative AUC over 4 days was 19.6 (range 14.1-27.2) mg ml-1 min-1. In 97 treatment days the carboplatin dose was calculated using the Calvert formula with the creatinine clearance as the measure for the glomerular filtration rate (GFR). For these courses, the inter-patient variability in pharmacokinetics was significantly reduced from 21% to 15% (P = 0.007) in comparison with the schemes where it was given as a fixed dose of 400 mg m-2. There were no relationships found between toxicity and the AUC of carboplatin, which may be due to the influence of overlapping toxicities of cyclophosphamide and thiotepa. However, the ototoxicity was strongly related to the cumulative carboplatin AUC. This toxicity was dose limiting for carboplatin in this schedule. It appeared that the carboplatin pharmacokinetics in these regimens were similar to those reported at conventional dosages. To reduce the inter-patient variation, the carboplatin dose can be calculated using the Calvert-formula with the creatinine clearance as the measure for the GFR